Fierce Biotech
Fierce Biotech heading to UK to host event amid London Life Sciences Week
Fierce Biotech is returning to the U.K. in November for a day of curated discussions and networking at The Savoy, London’s iconic hotel.
Medical Technology · page 6
Devices, digital health, and the technology changing how care is delivered.
Fierce Biotech
Beyond Rigid Platforms: Adaptive Adenoviral Platform De-Risks Development to GMP
Rigid adenoviral platforms can derail GMP progress. Learn how adaptive, adenovirus-specific strategies reduce risk from development to scale.
Fierce Biotech
Predicta links with Spanish university to offer diagnostic for blood cancers
Predicta Biosciences, a precision oncology specialist, is teaming with the Clínica Universidad de Navarra’s CIMA Lab Diagnostics clinic to offer an assay focused on blood cancers.
Fierce Biotech
Genentech executes another round of layoffs, with 3 VPs axed
Genentech vice presidents Vishva Dixit, Man-Wah Tan and Todd McDevitt are among the casualties in another round of layoffs from the South San Francisco subsidiary of Roche. The departures are part of a restructuring of the Genentech Research and Early Development (gRED) group. The company did not reveal how many positions are being affected.
Fierce Biotech
AI use is surging across HHS, jumping 148% at the FDA in 2025, Bipartisan Policy Center data finds
There was a big uptick in the use of AI across all HHS agencies in 2025, though analysts note some use cases may “reflect new reporting requirements instead of new deployments."
Fierce Biotech
Roche nabs EU approval on label expansions for companion dx platform
Roche received approval through the EU’s In Vitro diagnostic regulation for several label expansions of its companion diagnostic platform that can identify a cancer patient's mismatch repair (MMR) status.
Fierce Biotech
‘Not simply saving cost’: Inside Astellas CEO’s 5-year strategy to counter Xtandi’s patent cliff
Staring down a $6 billion patent cliff for its prostate cancer drug Xtandi, Astellas aims to counter the inevitable revenue decline with a 200 billion yen ($1.3 billion) cost-savings program anchored in its new five-year strategic plan. But to CEO Naoki Okamura, “it’s not simply saving the cost or reducing the headcount.”
Fierce Biotech
Fierce Biotech Layoff Tracker 2026: Genentech trims R&D; Neumora cuts 35%
As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.
Fierce Biotech
Novartis' phase 1/2 win tees up regulatory talks about dystrophy drug from $12B Avidity takeover
Novartis has reported a phase 1/2 win for one of the jewels of its $12 billion Avidity Biosciences buyout, setting the Swiss drugmaker up to talk to global regulatory agencies about the next steps for its dystrophy prospect.
Fierce Biotech
Chutes & Ladders—Perrigo CEO ousted over ‘personal conduct’
Over-the-counter drugmaker Perrigo Company is washing its hands of chief executive Patrick Lockwood-Taylor, who resigned from his post of president and CEO after the company’s board of directors found “certain personal conduct” by Lockwood-Taylor inconsistent with its code of conduct and “core values.” Board member Albert Manzone is stepping up to replace the CEO in the interim as the board searches for a permanent successor.
Fierce Biotech
Guardant Health nabs FDA test approval to find patients for Boehringer’s new cancer drug
Boehringer Ingelheim’s Hernexeos has nabbed a companion diagnostic from Guardant Health after the FDA cleared its liquid biopsy test, Guardant360 CDx.
Fierce Biotech
Ipsen R&D chief on pipeline discipline, partnerships and 2026 milestones
Christelle Huguet, Ph.D., Ipsen’s executive vice president and head of R&D, sits down with Fierce Healthcare & Life Sciences Editor-in-Chief Ayla Ellison to discuss pipeline discipline, external partnerships and key 2026 milestones.
Fierce Biotech
‘I wouldn’t call it a blip’: Biotech IPOs here to stay after another record-breaking listing
Elon Musk's SpaceX may be igniting global headlines with the company's astronomical IPO, but biotech listings saw their own record-breaker this week.
Fierce Biotech
Lilly unveils first clinical data behind $2.3B Ajax deal, showing JAK inhibitor works ‘right out of the gate’
Eli Lilly’s up-to-$2.3 billion acquisition of Ajax Therapeutics is facing its first major public test, and the initial clinical data show why the pharma giant made the bet.
Fierce Biotech
How NEC's AI and oral delivery system are redefining personalized cancer therapy
Neoantigen-based therapies are considered one of the most promising approaches in modern immuno-oncology. One challenge continues to limit the field: accurately identifying which neoantigens will generate meaningful anti-tumor immunity.
Fierce Biotech
Neumora to lay off 35% of staff after navacaprant goes 0 for 3 in late-stage depression studies
Neumora's navacaprant has completed a clean sweep of trial misses in major depressive disorder.
Fierce Biotech
Amgen loses in Harbour antibody patent case, ordered to pay $20M+
A federal jury in Delaware has found that Amgen and its acquired Teneobio willfully infringed on an antibody patent held by Harbour Antibodies, a Dutch subsidiary of China’s Harbour BioMed.
Fierce Biotech
Amid US investment tour, J&J makes $1B stop in Florida to upgrade contact lens plant
With Johnson & Johnson gradually fleshing out its $55 billion U.S. investment scheme in recent months, the New Jersey-headquartered drug and medical device giant on Monday revealed just how the plan will benefit its medtech operations, specifically in the field of vision care.